(Administrative Core) The Administrative Core provides essential support to the MD Anderson Cancer Center Prostate Cancer SPORE (Prostate Cancer SPORE) PIs and investigators to maximize success. It is directed by Drs. Christopher J. Logothetis and Timothy C. Thompson and co-directed by Dr. Sue-Hwa Lin, who co-chair the Executive Committee and provide overall supervision of 4 Projects, 2 additional Cores, Developmental Research (DRP) and Career Enhancement (CEP) Programs, and scientific direction of the SPORE. The Core Directors and co-Director rely on the extensive broad-based scientific, research, and SPORE experience of the Advisory Boards in critical decision-making. Success of the complex interdisciplinary research in the SPORE depends in part on integration of diverse prostate cancer research approaches. The Core will overcome barriers to interdisciplinary collaboration and data sharing and ensure a unified translational research effort. The SPORE is founded on planning, integration, and translational research efforts supported by this Core. Its leadership and staff will be responsible for monitoring/planning scientific activities; providing scientific direction; ensuring emphasis on translational research; ensuring interdisciplinary and inter-SPORE integration with major prostate programs within/outside MD Anderson and other broad translational research activities; and providing administrative and fiscal management (eg, personnel, budgets, office oversight, communication, organization of meetings, manuscript preparation, and progress and other reports to the NCI and SPORE committees, and support of Cores and Programs). Specific responsibilities of the Administrative Core are to: monitor research activity and provide stable and continuous leadership and direction; promote integration, communication, and collaboration among the SPORE and collaborating investigators at MD Anderson and other Texas Medical Center institutions; monitor scientific integrity and ensure overall compliance with all institutional, state, federal, and NCI regulations and requirements, as well as assurance for data quality control for the Biostatistics and Bioinformatics and Biospecimen and Pathology Cores; provide oversight for completion of DRP and CEP goals; convene, staff, and manage all necessary meetings; oversee expenditures and maintain budgets; communicate and consult with the NCI Translational Research Program Director and staff, including reports; increase awareness of prostate cancer research and patient advocacy in the community; address ongoing needs of minority and underserved communities in Houston and Harris County (Texas); and encourage and facilitate translational prostate cancer research by extramural groups within the region and throughout the US.

Public Health Relevance

(Administrative Core) The principal role of the Administrative Core of the MD Anderson Cancer Center Prostate Cancer SPORE is to expand the integration of investigators from diverse scientific disciplines who have joined the translational research effort in prostate cancer, and to provide continuous leadership and general administrative support for all SPORE-related activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA140388-06A1
Application #
8999523
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2009-09-02
Project End
2021-08-31
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
6
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Wang, Hong; Yang, Xu; Liu, Anna et al. (2018) ?-Tocopherol inhibits the development of prostate adenocarcinoma in prostate specific Pten-/- mice. Carcinogenesis 39:158-169
Velazquez-Torres, Guermarie; Shoshan, Einav; Ivan, Cristina et al. (2018) A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun 9:461
Zanoaga, Oana; Jurj, Ancuta; Raduly, Lajos et al. (2018) Implications of dietary ?-3 and ?-6 polyunsaturated fatty acids in breast cancer. Exp Ther Med 15:1167-1176
Zhang, Wei; Liu, Bo; Wu, Wenhui et al. (2018) Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res 24:696-707
Monroig-Bosque, Paloma Del C; Shah, Maitri Y; Fu, Xiao et al. (2018) OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. Sci Rep 8:13106
Basourakos, Spyridon P; Davis, John W; Chapin, Brian F et al. (2018) Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int 121:69-76
Pan, Tianhong; Lin, Song-Chang; Yu, Kai-Jie et al. (2018) BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia 20:32-43
Yu-Lee, Li-Yuan; Yu, Guoyu; Lee, Yu-Chen et al. (2018) Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGF?RIII-p38MAPK-pS249/T252RB Pathway. Cancer Res 78:2911-2924
Luo, Yong; Azad, Abul Kalam; Karanika, Styliani et al. (2018) Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. Int J Cancer 142:2163-2174
Soundararajan, Rama; Aparicio, Ana M; Logothetis, Christopher J et al. (2018) Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Front Oncol 8:69

Showing the most recent 10 out of 217 publications